Roche and Takeda’s Techpool to maximize Bondronat in China
This article was originally published in Scrip
Executive Summary
Roche has signed a contract with Takeda subsidiary Techpool Bio that will allow the Chinese pharma company exclusively to market the Swiss firm's oral bisphosphonate drug for bone metastases Bondronat (ibandronic acid) in China. The initial deal runs to 2017, with renewal possible depending on the performance of the product.